Project Grant R01HL176487
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
- The University of Cincinnati, through its Sponsored Research Services Division, was awarded a $156,276 project grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on "Hematopoietic Cells and Chemokine Regulation in Abdominal Aortic Aneurysm Associated Thrombosis". The project, with a performance period from August 1, 2025 to June 30, 2027, aims to investigate the role of platelet activation and...
- The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
- The University of Maryland, Baltimore received a $678,445 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to study a novel regulator of cardiomyocyte function and homeostasis. The research aims to determine the mechanisms by which the C5ORF51 (C5X) protein modulates transcription in cardiomyocytes and investigate its role in adult cardiomyocyte proliferation and maturation. This innovative research has the potential to uncover...
- The University of Cincinnati received a $728,776 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) effective September 3, 2025 with a completion date of May 31, 2029. The grant supports research to investigate the role of sphingolipid metabolism and signaling in the lung disease lymphangioleiomyomatosis (LAM), which primarily affects young women. The research aims to elucidate the molecular mechanisms by which the TSC2 gene...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- This $713,511 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the impact of myosin-binding protein C (MyBP-C) on myosin mobility and proteostasis in the context of hypertrophic cardiomyopathy (HCM). The University of Vermont & State Agricultural College, the awardee, will utilize innovative techniques to investigate how reduced MyBP-C levels, a common cause of HCM, may disrupt normal heart...
- The University of California, San Diego (UCSD) was awarded a $788,513 project grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to study the mechanisms underlying the maintenance of cardiac chamber identity in zebrafish. The research aims to elucidate the genetic pathways that reinforce ventricular cardiomyocyte identity, as ventricular myocardium harbors considerable plasticity and can transform to acquire atrial traits under certain...
- This $761,152 project grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of California, San Diego (UCSD) to investigate the gene regulatory mechanisms controlling the expression of cardiac myosin heavy chain proteins. The goal is to understand how shifts in the ratio of the MYH6 and MYH7 isoforms impact cardiac contractility, which is critical for heart function under both normal and disease...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
The University of Cincinnati was awarded a $698,432 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on "Stress Regulated RNA Degradation in Cardiac Hypertrophy." The project aims to establish the role of the UPF1 RNA helicase and the RBFOX1C RNA binding protein in regulating mRNA degradation in response to cardiac stress, and to determine the functional significance of this stress-regulated mRNA degradation pathway in cardiac hypertrophy. The research will leverage modern molecular sequencing techniques and mouse cardiac disease models over the project period from September 1, 2025 to May 31, 2030. This grant award supports the university's extensive cardiovascular research capabilities and aligns with the NHLBI's objectives to advance basic, translational, and clinical research on heart and vascular health.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $698.4k | 8/28/25 |